In 2025–2026, two major trends became more visible in international psychiatry. The first is a stronger professional push toward earlier and more appropriate use of clozapine in treatment-resistant schizophrenia. The second is the emergence of new non-dopaminergic treatments, especially xanomeline/trospium (Cobenfy), which reflects a broader search for alternative mechanisms in antipsychotic therapy.
In 2025–2026, two major trends became more visible in international psychiatry. The first is a stronger professional push toward earlier and more appropriate use of clozapine in treatment-resistant schizophrenia. The second is the emergence of new non-dopaminergic treatments, especially xanomeline/trospium (Cobenfy), which reflects a broader search for alternative mechanisms in antipsychotic therapy.
Clozapine itself is not a new drug, but the clinical conversation around it is changing. Professional organizations are emphasizing that the main problem today is not a lack of evidence, but the fact that clozapine is still often introduced too late in patients who already meet criteria for treatment-resistant schizophrenia. This matters because earlier initiation after a clear TRS diagnosis is associated with better outcomes.
At the same time, regulatory changes in the United States have reduced some practical barriers around clozapine. After the FDA removed the Clozapine REMS program, the discussion shifted toward how to maintain appropriate safety monitoring while improving access. This is important because one of the most effective treatments in schizophrenia should not remain underused mainly for administrative reasons.
Alongside this, psychiatry is also moving toward new pharmacological strategies. Cobenfy, a combination of xanomeline and trospium, was approved by the FDA as the first schizophrenia treatment in decades with a new mechanism of action. Unlike standard antipsychotics, which primarily rely on dopamine receptor blockade, this treatment targets the muscarinic cholinergic system. That makes it clinically important, not because it replaces established therapy, but because it expands the therapeutic landscape.
Its clinical role, however, should be described carefully. Cobenfy is an important innovation, but it does not replace clozapine in treatment-resistant schizophrenia. Clozapine still has the strongest evidence base for TRS, while newer agents currently represent an additional option rather than a proven replacement in the most difficult cases. Long-term data on xanomeline/trospium are encouraging, but they are not equivalent to the decades of clinical experience and evidence supporting clozapine in resistant illness.
So the modern strategy is not “old versus new.” It is more accurate to say that psychiatry is moving toward better stratification. Clozapine remains the key evidence-based choice when resistance is established. Newer agents may be useful earlier in treatment pathways, in selected patients, or in situations where mechanism, tolerability, or treatment goals justify a different approach.
This trend appears clinically justified. The renewed emphasis on clozapine is evidence-based and reflects a correction of underuse rather than a change in the science itself. The development of new agents such as xanomeline/trospium is also scientifically meaningful, but still requires continued accumulation of long-term data, comparative experience, and real-world evaluation.
In practical terms, the current direction in schizophrenia treatment is becoming clearer: use clozapine more timely when true resistance is present, and use new agents to broaden options rather than to displace the best-supported treatment for the most severe cases.
Sources: FDA approval of Cobenfy and its cholinergic mechanism; FDA removal of Clozapine REMS; Royal College of Psychiatrists Position Statement PS01/26 on timely clozapine use; 52-week open-label EMERGENT-5 data on xanomeline/trospium.
Author: IsraClinic – Private Psychiatric Expert Clinic